Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Shareholders??? Equity (Details)

v3.22.1
Shareholders’ Equity (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Dec. 13, 2021
Sep. 13, 2020
Aug. 05, 2020
Jun. 04, 2020
Aug. 28, 2021
Jan. 27, 2021
Oct. 28, 2020
Aug. 30, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2009
Mar. 07, 2021
Shareholders’ Equity (Details) [Line Items]                        
Gross amount $ 16,994   $ 6,067                  
Ordinary shares issued (in Shares) 3,892,152                      
Gross proceeds $ 15,966                      
Total investments           $ 9,000            
Discount on the average percentage           20.00%            
Total Investment percentage           60.00%            
Number of shares issue (in Shares)                       6,891,418
Investment description                 The second tranche of $6,000 was due following the approval of the listing of the Company’s securities on Nasdaq (the “Second Closing Milestone” and such date, “the Second Closing Date”). In May 2021, the Company and the investors agreed to execute the second tranche prior to the achievement of the Second Closing Milestone, and the second tranche of $6,000 was received on May 9, 2021. Accordingly, the Company issued to the investors 4,594,279 shares.       
Authorized share capital (in Shares)   2,500,000,000                    
Reverse stock split                 Accordingly, all option numbers, share numbers, share prices, exercise prices and losses per share have been adjusted within these consolidated financial statements, on a retroactive basis, to reflect this 8-for-1 reverse stock split.      
Ordinary shares forfeited (in Shares)                     5,434  
Ordinary shares approximately                   $ 41  
Outstanding and exercisable options (in Shares)                 846,105,000      
Aggregate intrinsic value                 $ 1,321      
Fair value granted options per share (in Dollars per share)                 $ 6.89      
Unrecognized share-based compensation cost                 $ 217      
Remaining vesting period                 4 years      
Common Stock [Member]                        
Shareholders’ Equity (Details) [Line Items]                        
Investors shares (in Shares)           11,485,697            
Shares price (in Dollars per share) $ 3.449         $ 1.304            
Number of shares issue (in Shares) 1,034,000                      
Warrant [Member]                        
Shareholders’ Equity (Details) [Line Items]                        
Shares price (in Dollars per share) $ 0.001                      
IPO [Member]                        
Shareholders’ Equity (Details) [Line Items]                        
Ordinary shares issued (in Shares)     5,175,000                  
Ordinary shares price per share (in Dollars per share)     $ 1.168                  
Gross proceeds     $ 5,847                  
Over-Allotment Option [Member]                        
Shareholders’ Equity (Details) [Line Items]                        
Shares price (in Dollars per share) $ 3.45                      
Number of shares issue (in Shares) 578,325                      
Capital Support Agreement [Member]                        
Shareholders’ Equity (Details) [Line Items]                        
Total investments           $ 15,000            
Business Combination [Member] | Chief Executive Officer [Member]                        
Shareholders’ Equity (Details) [Line Items]                        
Stock option description       the Company granted 142,594 options to purchase an aggregate of 142,594 ordinary shares to 27 employees of the Company, at an exercise price of $1.68 per share. The options will vest in four equal installments over a period of four years from the date of grant. The options are exercisable for 10 years from the date of grant. the Company granted 8,929 options to purchase an aggregate of 8,929 ordinary shares to five officers of the Company, as follows: 4,319 options for the Company’s CEO, and 4,610 options for four officers, at an exercise price of $5.76 per share. The options will vest as follows: a quarter after one year and the rest will vest in 12 equal quarterly installments over a period of three years from April 28, 2022. The options are exercisable for 10 years from the date of grant.   the Company granted 57,500 options to purchase an aggregate of 57,500 ordinary shares to 2 officers of the Company, as follows: 32,500 options for the Company’s CEO, and 25,000 options for the Chairman of the Board of Directors, at an exercise price of $1.60 per share. The options will vest as follows: a quarter after one year and the rest will vest in 12 equal quarterly installments over a period of three years from October 28, 2021. The options are exercisable for 10 years from the date of grant. the Company granted 170,258 options to purchase an aggregate of 170,258 ordinary shares to six officers of the Company, as follows: 27,333 options for the Company’s CEO, and 142,925 options for five officers of the Company, at an exercise price of $1.52 per share. The CEO’s options will vest in 16 equal quarterly installments over a period of four years from the date of grant. The officer’s options will vest as follows: a quarter after one year and the rest will vest in 12 equally quarterly installments over a period of three years from August 30, 2021. The options are exercisable for 10 years from the date of grant.        
Options exercise description                 the Company granted 100,000 options to purchase an aggregate of 100,000 ordinary shares to a member of the Company’s Board of directors, at an exercise price of $1.60 per share. The options will vest as follows: a.25,000 options - a quarter after one year and the rest will vest in 12 equal quarterly installments over a period of three years from December 13, 2020.  b.75,000 options- based on target achievement:  i.37,500 options will vest and become exercisable, on the date of receipt by the company of two regulatory approvals in China from the NMPA (National Medical Products Administration) for the marketing and sale of ProSense product and for the sale of probes of the company, and no later than December 31, 2022.  ii.37,500 options will vest and become exercisable, with the sale of a Consoles and Probes as determined in the options agreemet in one calendar year in Chinese territory, and no later than the end of 2024. The options are exercisable for 10 years from the date of grant.       
Epoch Partner Investments Limited [Member]                        
Shareholders’ Equity (Details) [Line Items]                        
Total working capital           7,500            
Alpha Capital Anstalt [Member]                        
Shareholders’ Equity (Details) [Line Items]                        
Total working capital           4,000            
Clover Wolf Capital Limited [Member]                        
Shareholders’ Equity (Details) [Line Items]                        
Total working capital           3,100            
Clover Alpha L.P [Member]                        
Shareholders’ Equity (Details) [Line Items]                        
Total working capital           $ 400